Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy : lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial | Macquarie University ResearchOnline

Home

Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy : lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial

Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.14/112827

32 Visitors

36 Hits

1 Downloads

Title: Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy : lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial
Related: American heart journal, Vol. 159, No. 6 (2010), p.988-997
DOI: 10.1016/j.ahj.2009.12.044
Publisher: Elsevier
Date: 2010
FoR/RFCD Code(s): 110201 Cardiology (incl. Cardiovascular Diseases) 010402 Biostatistics
Author/Creator: Simes, R. John
Author/Creator: O'Connell, Rachel L
Author/Creator: Marschner, Ian C
Author/Creator: Califf, Rob
Author/Creator: White, Harvey D
Author/Creator: Aylward, Philip E
Author/Creator: Varshavsky, Sergei
Author/Creator: Diaz, Rafael
Author/Creator: Wilcox, Robert G
Author/Creator: Armstrong, Paul W
Author/Creator: Granger, Christopher B
Author/Creator: French, John K
Author/Creator: Van de Werf, Frans
Description: Background: Despite advances in therapy, global mortality due to acute myocardial infarction remains high. The international Hirulog and Early Reperfusion or Occlusion (HERO-2) trial of 17,073 patients with ST-segment elevation myocardial infarction provided the opportunity to explore international differences in outcomes. Methods: Patient characteristics, treatment, and outcomes were compared across 5 diverse regions: Western countries, Latin America, Eastern Europe, Russia, and Asia. In addition, a representative sample of 1,743 screened patients was compared with enrolled patients. Results: Larger percentages of eligible patients were randomized in Eastern Europe, Russia, and Asia than Western countries. These regions enrolled more patients with anterior myocardial infarction, Killip class III or IV, and late presentation (>4 hours). More patients aged >75 years were enrolled from Western countries. Overall risk levels were similar. Eastern Europe and Russia had lower rates than Western countries of coronary revascularization (2% vs 18%) and longer hospital stays (median 18 vs 7 days). Thirty-day mortality was lower in Western countries; 6.7% versus 10.2% to 13.2% elsewhere, whereas reinfarction was more frequent (3.2% vs 1.5% to 3.0%; each, P < .001). Regional mortality differences persisted after adjustment for baseline risk factors, treatments, or national health and economic statistics (each P < .001). Conclusions: The variation in mortality and other clinical outcomes across geographic regions was not adequately explained by risk factors, patterns of care, or national health statistics. Nevertheless, large international trials are a better way to assess potential new treatments across many countries than the alternative of separate smaller trials in each region.
Description: 10 page(s)
Subject Keyword: 110201 Cardiology (incl. Cardiovascular Diseases)
Subject Keyword: 010402 Biostatistics
Resource Type: journal article
Organisation: Macquarie University. Dept. of Statistics

Identifier: http://hdl.handle.net/1959.14/112827
Identifier: ISSN:1097-6744
Identifier: mq-rm-2010000342
Language: eng
Reviewed

Macquarie University ResearchOnline

Search

Browse

Highlights

Resources